quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:36:17·141d
INSIDERFiling
Integral Ad Science Holding Corp. logo

Chief Accounting Officer Gil Alexis Ii sold $28,589 worth of shares (2,781 units at $10.28), decreasing direct ownership by 2% to 136,840 units (SEC Form 4)

IAS· Integral Ad Science Holding Corp.
Technology
Original source

Companies

  • IAS
    Integral Ad Science Holding Corp.
    Technology

Recent analyst ratings

  • Mar 28UpdateRobert W. Baird$9.00
  • Dec 5UpdateScotiabank$10.00
  • Apr 30UpdateLoop Capital$15.00
  • Apr 16UpdateMorgan Stanley$12.00
  • Feb 28UpdateRaymond James$16.00
  • Jan 11UpdateBofA Securities$19.00

Related

  • SEC111d
    SEC Form 15-12G filed by Integral Ad Science Holding Corp.
  • SEC115d
    Amendment: SEC Form SCHEDULE 13G/A filed by Integral Ad Science Holding Corp.
  • INSIDER115d
    Large owner Vep Group, Llc disposed of $669,603,010 worth of shares (65,010,001 units at $10.30) (SEC Form 4)
  • SEC121d
    Amendment: SEC Form SCHEDULE 13G/A filed by Integral Ad Science Holding Corp.
  • INSIDER121d
    Large owner Atlas Venture Fund Viii, L.P. disposed of $234,044,531 worth of shares (22,722,770 units at $10.30) (SEC Form 4)
  • INSIDER121d
    Director Lord Robert returned $300,595 worth of shares to the company (29,184 units at $10.30), closing all direct ownership in the company (SEC Form 4)
  • INSIDER121d
    Chief Financial Officer Wegner Alpana returned $5,410,374 worth of shares to the company (525,279 units at $10.30), closing all direct ownership in the company (SEC Form 4)
  • INSIDER121d
    Director Putman Jill returned $1,363,256 worth of shares to the company (132,355 units at $10.30), closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022